Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms
Cephalexin

Dose and Indications

**Infection due to susceptible organisms**

**Oral**

25mg/kg per dose (maximum dose 125mg)

<table>
<thead>
<tr>
<th>Age (days)</th>
<th>Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 7</td>
<td>every 12 hours</td>
</tr>
<tr>
<td>7 to 21</td>
<td>every 8 hours</td>
</tr>
<tr>
<td>&gt;21</td>
<td>every 6 hours</td>
</tr>
</tbody>
</table>

While dosing guidelines are not published for premature neonates, the dosing interval should be at least 12 hours in neonates with poor kidney function.

Length of treatment should be guided by pathology and clinical picture.

**Prophylaxis of recurrent urinary tract infections**

**Oral**

12.5mg/kg once a day at night

**Prophylaxis for Micturating Cystourethrogram (MCUG)**

**Oral**

12.5mg/kg/dose 8 hourly for 3 days, with MCUG taking place on the second day
Preparation and Administration

**Oral**

To reconstitute dry powder, use water for injection and add the volume specified on the packaging.

The reconstituted solution is usually stable for 14 days stored under refrigeration; however, this may change according to brand available. Please consult product information.

Shake well before use.

Cefalexin may be given without regard to food

**Adverse Effects**

**Common**

Diarrhoea, vomiting, rash, *Clostridium difficile*-associated disease, superinfection

**Infrequent**

Neurotoxicity (seizures, encephalopathy) particularly with high doses and/or renal impairment, blood dyscrasias (neutropenia related to dose and treatment duration, thrombocytopenia), cholestatic hepatitis, antibiotic-associated colitis

Anaphylactic shock is not commonly seen in neonates

**Practice Points**

- Cefalexin may cause a false positive Coomb's test

**Reference**

- Urinary tract infections in under 16s: diagnosis and management, 2007, Clinical Guideline, National Institution for Health and Care Excellence, accessed online February 2022
## Document Ownership & History

<table>
<thead>
<tr>
<th>Developed by:</th>
<th>SA Maternal, Neonatal &amp; Gynaecology Community of Practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact:</td>
<td><a href="mailto:Health.NeoMed@sa.gov.au">Health.NeoMed@sa.gov.au</a></td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
</tr>
<tr>
<td>Next review due:</td>
<td>29/06/2027</td>
</tr>
<tr>
<td>ISBN number:</td>
<td>978-1-76083-504-0</td>
</tr>
<tr>
<td>CGSQ reference:</td>
<td>NMG022</td>
</tr>
</tbody>
</table>

### Policy history:
- **Is this a new policy (V1)?** N
- **Does this policy amend or update an existing policy?** Y
  - If so, which version? **V 2.0**
- **Does this policy replace another policy with a different title?** N

### Approval Date

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>29/06/22</td>
<td>V3.0</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
<td>Formally reviewed in line with 5 year scheduled timeline for review.</td>
</tr>
<tr>
<td>9/11/2017</td>
<td>V2.0</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Complete review</td>
</tr>
</tbody>
</table>